Population‐based cohort study of the management and survival of patients with early‐stage oesophageal adenocarcinoma in England. BJS 2016; 103: 544-552.
Published: 11th February 2016
Authors: G. Chadwick, S. Riley, R. H. Hardwick, T. Crosby, J. Hoare, G. Hanna et al.
Until recently, oesophagectomy was the treatment of choice for early oesophageal cancer. Endoscopic treatment has been introduced relatively recently. This observational national database study aimed to describe how endoscopic therapy has been introduced in England and to examine the safety of this approach.
A population‐based cohort study was undertaken of patients diagnosed with oesophageal adenocarcinoma between October 2007 and June 2009 using three linked national databases. Patients with early‐stage disease (
Of 5192 patients diagnosed with oesophageal adenocarcinoma, 306 (5·9 per cent) were considered to have early‐stage disease before any treatment, of whom 239 (79·9 per cent of 299 patients with data on treatment intent) were managed with curative intent. Of 175 patients who had an oesophagectomy, 114 (65·1 (95 per cent c.i. 57·6 to 72·7) per cent) survived for 5 years. Among these, 47 (30·3 per cent of 155 patients with tissue results available) had their disease upstaged after pathological staging; this occurred more often in patients who did not have staging endoscopic ultrasonography before surgery. Of 41 patients who had an endoscopic resection, 27 (66 (95 per cent c.i. 49 to 80) per cent) survived for 5 years. Repeat endoscopic therapy was required by 23 (56 per cent) of these 41 patients.
Between 2007 and 2009, oesophagectomy remained the initial treatment of choice (73·2 per cent) among patients with early‐stage oesophageal cancer treated with curative intent; one in five patients were managed endoscopically, and this treatment was more common in elderly patients. Although the groups had different patient characteristics, 5‐year survival rates were similar.Full text
You may also be interested in
Randomized clinical trial
Health‐related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
Authors: B. Sunde, F. Klevebro, A. Johar, G. Johnsen, A.‐B. Jacobsen, N. I. Glenjen et al.
Morphological lymphocytic reaction, patient prognosis and PD‐1 expression after surgical resection for oesophageal cancer. BJS 2019; 106: 1352-1361.
Authors: Y. Baba, T. Yagi, K. Kosumi, K. Okadome, D. Nomoto, K. Eto et al.
Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases. BJS 2019; 106: 1372-1380.
Authors: Å. A. Fretland, V. J. Dagenborg, G. M. Waaler Bjørnelv, D. L. Aghayan, A. M. Kazaryan, L. Barkhatov et al.
Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. BJS 2019; 106: 1341-1351.
Authors: J. A. Elliott, L. O'Byrne, G. Foley, C. F. Murphy, S. L. Doyle, S. King et al.
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction.
Authors: W. H. Allum, E. C. Smyth, J. M. Blazeby, H. I. Grabsch, S. M. Griffin, S. Rowley et al.
Meta‐analysis of randomized clinical trials of early versus delayed cholecystectomy for mild gallstone pancreatitis.
Authors: N. Moody, A. Adiamah, F. Yanni, D. Gomez
Authors: Y. Y. Broza, S. Khatib, A. Gharra, A. Krilaviciute, H. Amal, I. Polaka et al.
Authors: S. Ahlin, C. Cefalù, I. Bondia‐Pons, E. Capristo, L. Marini, A. Gastaldelli et al.
Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy.
Authors: J. X. Lin, C. Yoon, J. Desiderio, B. C. Yi, P. Li, C. H. Zheng et al.
Hepatectomy for hepatocellular carcinoma after perioperative management of portal hypertension. BJS 2019; 106: 1066-1074.
Authors: N. Takemura, T. Aoki, K. Hasegawa, J. Kaneko, J. Arita, N. Akamatsu et al.
Meta‐analysis of risk factors and complications associated with atrial fibrillation after oesophagectomy. BJS 2019; 106: 534-547.
Authors: D. Schizas, M. Kosmopoulos, S. Giannopoulos, S. Giannopoulos, D. G. Kokkinidis, N. Karampetsou et al.